CHANGES OF ANGIOGENIC FACTORS AND MARKERS OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADOLESCENTS OF WILSON-KONOVALOV DISEASE

Abstract

Although angiogenesis is an integral part of tumor progression, it has also been observed in different inflammatory, fibrotic, and ischemic diseases. Angiogenesis is a multifactorial process and its changes bring essential information about the status of complex pathology. Aim: evaluate the role of angiogenesis and endothelial dysfunction factors in Wilson-Konovalov disease (WKD) in children and adolescents. Methods: 19 children and adolescents with WKD were included in the study. VEGF-A, angiotensin (ANG), soluble receptors of VEGF-A (sVEGF-R1 и sVEGF-R2) and trombomodulin have been investigated in serum by enzyme immunoassay using special kits (BCM Diagnostics, USA). Other endothelial dysfunction markers as von Willebrand factor (vWf) was determined in blood plasma by immunoturbidimetry (Siemens, Germany), plasminogen (PLG) was investigated due to extended coagulation. Results: it was founded marked decreasing of VEGF-A and increasing concentration of sVEGF-R1, sVEGF-R2 in blood plasma of WKD children and adolescence by comparison of reference group. ANG did not change. Comparing the ratio of levels VEGF-A+ANG/sVEGF-R1+sVEGF-R2 (in children with WKD 16,7±1,9 and in reference group 23,0±1,6, р<0,05), we have revealed the deficiency of pro-angiogenic factors that can be helpful in characterizing of angiogenic activity. At the same time, the level of TM and the percentage of PLG and vWf increased. Conclusion: it was revealed correlation between studied markers and liver damage, concomitant diseases and the presence of chronic infection, as well as a number of other parameters.

Keywords

sVEGF-R2 / hepatic angiogenesis / endothelial dysfunction / Wilson-Konovalov disease / vascular endothelial growth factor (VEGF-A) / soluble vascular endothelial growth factor receptor 1, 2 / angiogenin / trombomodulin / plasminogen / Willebrand factor

References

[1] Гарбузенко Д.В. Морфофункциональная перестройка печеночного сосудистого русла в патогенезе портальной гипертензии при циррозе печени (обзор литературы). Терапевтический архив. 2014; 2: 90-5

[2] Lozano R., Naghavi M., Foreman K., Lim S., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2095-0128. doi: 10.1016/S0140-6736(12) 61728-0

[3] Folkman J. Angiogenesis: in organizing principle for drug discovery? Nat.Rev.Drug.Discov. 2007. 6(4): 273-286. doi: 10.1038/nrd2115

[4] Salsedo X., Medina J., Sanz-Cameno P., Garcia-Buey L., Martin-Vilchez S., Moreno-Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol. Ther. 2005; 22: 23-30. doi: 10.1111/j.1365-2036.2005.02532.x

[5] Fernández-Iglesias A., Gracia-Sancho J. How to Face Chronic Liver Disease: The Sinusoidal Perspective. Front Med (Lausanne). 2017; 4 (7): 1-10. doi: 10.3389/fmed.2017.00007

[6] Гарбузенко Д.В. Механизмы компенсации структуры и функции печени при ее повреждении и их практическое значение. Рос. журнал гастроэнтерологии, гепатологии, колопроктологии. 2008; 6 (XVIII): 14-21

[7] Makhlouf M.M., Awad A., Zakhari A.A. et al. Vascular endothelial growth factor level in chronic liver diseases. J. Egypt. Soc. Parasitol. 2002; 32 (3): 907-21

[8] Батырова А.С., Баканов М.И., Сурков А.Н. Состояние системы ремоделирования сосудов и ангиогенеза печени при хронических формах её патологии (обзор литературы). Патологическая физиология и экспериментальная терапия. 2016; 60 (1): 73-8.

[9] Парфенова Е.В., Ткачук В.А. Терапевтический ангиогенез: достижения, проблемы, перспективы. Кардиологический вестник. 2007; 2: II (XIV): 5-15.

[10] Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M., Mihu C., Istrate M. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol. Embryol. 2018. 59(2): 455-67.

[11] Sharma PS., Sharma R., Tyagi T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr. Cancer Drug Targets. 2011; 11 (5): 624-53.

[12] Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298-307. doi: 10.1038/nature10144

[13] Wu F.T.H., Stefanini MO., Gabhann FM., Kontos CD., Annex BH. et. al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J. Cell. Mol. Med. 2010; 14 (3): 528-52. doi: 10.1111/j.1582-4934.2009.00941.x

[14] Tripodi A., Mannuccio P. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365(2): 147-56. doi: 10.1056/NEJMra1011170

[15] Cahill P.A., Redmond E.M., Sitzmann J.V. Endothelial dysfunction in cirrosis and portal hypertension. Pharmacol. Ther. 2001; 89: 273-93

[16] Батырова А.С., Баканов М.И., Сурков А.Н. Современные представления о системе гемостаза при хронических заболеваниях печени (обзор литературы). Клиническая лабораторная диагностика. 2015; 60 (8): 40-4

RIGHTS & PERMISSIONS

Eco-Vector